Search NASA⌕ Search

SEARCH · Search NASA

Results for “IRIDIUM ISOTOPES”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 records

Discovery of tantalum, rhenium, osmium, and iridium isotopes

Currently, thirty-eight tantalum, thirty-eight rhenium, thirty-nine osmium, and thirty-eight iridium isotopes have been observed and the discovery of these isotopes is described here. For each isotope a brief synopsis of the first refereed publication, including the production and identification method, is presented.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Comparison of model predictions with measured proton-induced production of nickel and iridium isotopes

Calculations were performed to support method development for simultaneous production of Ni and Ir isotopes. Here, the work scope included development of the physical target, irradiation configuration, and post-irradiation radiochemical separations. The assumptions of predictive models previously developed were refined based upon the precise experimental configuration selected, including Os target material and a set of stacked targets for concurrent production of Ni and Ir isotopes. Model predictions of the reaction cross sections with EMPIRE 3.21 and implied isotopic yields are compared with proton beam irradiation measurements to refine model parameters and guide future experiments.

Isotope Production↗

Semiphenomenological approximation of the sums of experimental radiative strength functions for dipole gamma transitions of energy E{sub {gamma}}below the neutron binding energy B{sub n} for mass numbers in the range 40 {<=} A {<=} 200

The sums of radiative strength functions for primary dipole gamma transitions, k(E1) + k(M1), are approximated to a high precision by a superposition of two functional dependences in the energy range 0.5 < E{sub 1} < B{sub n} - 0.5 MeV for the {sup 40}K, {sup 60}Co, {sup 71,74}Ge, {sup 80}Br, {sup 114}Cd, {sup 118}Sn, {sup 124,125}Te, {sup 128}I, {sup 137,138,139}Ba, {sup 140}La, {sup 150}Sm, {sup 156,158}Gd, {sup 160}Tb, {sup 163,164,165}Dy, {sup 166}Ho, {sup 168}Er, {sup 170}Tm, {sup 174}Yb, {sup 176,177}Lu, {sup 181}Hf, {sup 182}Ta, {sup 183,184,185,187}W, {sup 188,190,191,193}Os, {sup 192}Ir, {sup 196}Pt, {sup 198}Au, and {sup 200}Hg nuclei. It is shown that, in any nuclei, radiative strength functions are a dynamical quantity and that the values of k(E1) + k(M1) for specific energies of gamma transitions and specific nuclei are determined by the structure of decaying and excited levels, at least up to the neutron binding energy B{sub n}.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Nuclear Data Sheets for A = 168

Nuclear structure data pertaining to all nuclei with mass A=168 (Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir, Pt) have been evaluated and incorporated into the ENSDF data file. This evaluation supersedes the previous publication (V.S. Shirley, Nuclear Data Sheets 71, 261 (1994) (literature cutoff date July 1993)) and subsequent ENSDF file revisions for Tb and Dy (C. Baglin, literature cutoff date of 15 June 1999) and Hf (B. Singh, literature cutoff date of 30 April 2001), and includes literature available by 15 June 2010. Since the above evaluations, the first excited states in {sup 168}Pt have been identified (1998Ki20, 2009Go16) and {alpha} decay from {sup 172}Hg has been observed (2009Sa27, 2004Ke06, 1999Se14). New levels in {sup 168}Dy have been excited using the {sup 170}Er({sup 82}Se,{sup 84}Kr{gamma}) reaction (2010So03). (HI,xn{gamma}) studies have significantly expanded our knowledge of level structure in {sup 168}Lu (1999Ka17, 2002Ha33), {sup 168}Ta (2008QiZZ), {sup 168}Yb (1995Fi01), {sup 168}Tm (2007CaZW), {sup 168}Hf (2009Ya21), {sup 168}Os (2001Jo11, 2009Od02) and, for {sup 168}Tm, important information has come also from (d,2n{gamma}) and ({alpha},n{gamma}) reactions (1995Si20). Revised decay schemes are available following new studies of {sup 168}Hf {epsilon} decay (6.7 min) (1997Ba26), {sup 168}Lu {epsilon} decay (1999Ba65), {sup 168}Ta {epsilon} decay (2007Mc08) and {sup 172}Au {alpha} decay (2009Ha42). Significant new information for {sup 168}Er is available from (p,t) (2006Bu09), (d,p) and (t,d) (1996Ma50), ({gamma},{gamma}') (1996Ma18), (136Xe, X{gamma}) (2010Dr02), ({sup 238}U,{sup 238}U{sup '{gamma}}) (2003Wu07) and (n,n{sup '{gamma}}) (1998Be20, 1998Be62) reactions, and the availability of {gamma}{gamma} coin data (1994Ju02, 1996Gi09) for the (n,{gamma}) E=thermal reaction has resulted in some significant level scheme revisions.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Synthesis of N=127 isotones through (p,n) charge-exchange reactions induced by relativistic {sup 208}Pb projectiles

The production cross sections of four N=127 isotones ({sup 207}Hg, {sup 206}Au, {sup 205}Pt, and {sup 204}Ir) have been measured using (p,n) charge-exchange reactions, induced in collisions of a {sup 208}Pb primary beam at 1 A GeV with a Be target. These data allow one to investigate the use of a reaction mechanism to extend the limits of the chart of nuclides toward the important r-process nuclei in the region of the third peak of elemental abundance distribution.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Nuclear Data Sheets for A=182

Nuclear spectroscopic information for known nuclides of mass number 182 (Lu,Hf,Ta,W,Re,Os,Ir,Pt,Au,Hg, Tl,Pb) with Z=71 to 82 and N=111 to 100 have been evaluated and presented together with adopted energies and J{pi} of levels in these nuclei. No excited state data are yet available for {sup 182}Lu, while only limited structure information is available for {sup 182}Pb and {sup 182}Tl. Rotational band structures are known for {sup 182}Hg and {sup 182}Au but spin-parity assignments remain largely tentative. The decays of {sup 182}Lu, {sup 182}Hg, {sup 182}Au and {sup 182}Tl are not well established. The {sup 182}Hf isotope is of geophysical and astrophysical interest. This evaluation supersedes previous full evaluations of A=182 published by 1988Fi05 and 1975Sc13, and a selected (mainly high-spin) update of A=182 published by 1995Si04.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Is Elective Irradiation to the Lower Neck Necessary for N0 Nasopharyngeal Carcinoma?

Purpose: To summarize our experience and treatment results in lymph node-negative nasopharyngeal carcinoma treated in a single institution. Methods and Materials: From January 2000 to December 2003, 410 patients with lymph node-negative nasopharyngeal carcinoma were retrospectively analyzed. The T-stage distribution was 18.8% in T1, 54.6% in T2 (T2a, 41 patients; T2b, 183 patients), 13.2% in T3, and 13.4% in T4. All patients received radiotherapy to the nasopharynx, skull base, and upper neck drainage areas, including levels II, III, and VA. The dose was 64-74 Gy, 1. 8-2.0 Gy per fraction over 6.5-7.5 weeks to the primary tumor with {sup 60}Co or 6-MV X-rays, and 50-56 Gy to levels II, III, and VA. Residual disease was boosted with either {sup 192}Ir afterloading brachytherapy or small external beam fields. Results: The median follow-up time was 54 months (range, 3-90 months). Four patients developed neck recurrence, and only 1 patient (0.2%) experienced relapse outside the irradiation fields. The 5-year overall survival rate was 84.2%. The 5-year relapse-free survival rate, distant metastasis-free survival rate, and disease-free survival rate were 88.6%, 90.6% and 80.1%, respectively. Both univariate and multivariate analyses demonstrated that T classification was the only significant prognostic factor for predicting overall survival. The observed serious late toxicities were radiation-induced brain damage (7 cases), cranial nerve palsy (16 cases), and severe trismus (13 cases; the distance between the incisors was {<=}1 cm). Conclusion: Elective levels II, III, and VA irradiation is suitable for nasopharyngeal carcinoma without neck lymph node metastasis.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Usefulness of Intraluminal Brachytherapy Combined With External Beam Radiation Therapy for Submucosal Esophageal Cancer: Long-Term Follow-Up Results

Purpose: To assess the efficacy of radiation therapy (RT) by using intraluminal brachytherapy (IBT) combined with external beam RT (EBRT) for submucosal esophageal cancer. Methods and Materials: Between 1991 and 2005, 59 consecutive patients received definitive RT without chemotherapy. IBT was performed after patients completed EBRT as a booster therapy for 17 patients, using low-dose-rate Cs-137 sources until 1997, and for 19 patients, using high-dose-rate Ir-192 sources thereafter. The long-term outcomes were investigated with a median follow-up time of 61 months. Results: Logoregional recurrences and distant metastases were observed in 14 patients and in 2 patients in the lung, respectively, and 5 patients were rescued by salvage treatments. The 5-year logoregional control and cause-specific survival rates were 75% and 76%, respectively. The 5-year cause-specific survival rate in the EBRT group was 62%, whereas the corresponding rate in the IBT group was 86% (p = 0.04). Multivariate analysis revealed that IBT was the most powerful predictor of survival but did not reach a significant level (p = 0.07). There were five esophageal ulcers in the IBT group, but no ulcers developed with small fractions of 3 Gy. Grade 2 or higher cardiorespiratory complications developed in 2 patients (5.6%) in the IBT group and in 3 patients (13.0%) in the EBRT group. Conclusions: Combining IBT with EBRT is suggested to be one of the preferable treatment modalities for medically inoperable submucosal esophageal cancer because of its preferable local control and survival probabilities, with appreciably less morbidity.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Evaluation of Scatter Contribution and Distance Error by Iterative Methods for Strength Determination of HDR {sup 192}Ir Brachytherapy Source

High-dose rate (HDR) {sup 192}Ir brachytherapy sources are commonly used for management of malignancies by brachytherapy applications. Measurement of source strength at the hospital is an important dosimetry requirement. The use of 0.6-cm{sup 3} cylindrical ionization chamber is one of the methods of measuring the source strength at the hospitals because this chamber is readily available for beam calibration and dosimetry. While using the cylindrical chamber for this purpose, it is also required to determine the positioning error of the ionization chamber, with respect to the source, commonly called a distance error (c). The contribution of scatter radiation (M{sub s}) from floor, walls, ceiling, and other materials available in the treatment room also need to be determined accurately so that appropriate correction can be applied while calculating the source strength from the meter reading. Iterative methods of Newton-Raphson and least-squares were used in this work to determine scatter contribution in the experimentally observed meter reading (pC/s) of a cylindrical ionization chamber. Monte Carlo simulation was also used to cross verify the results of the least-squares method. The experimentally observed, least-squares calculated and Monte Carlo estimated values of meter readings from HDR {sup 192}Ir brachytherapy source were in good agreement. Considering procedural simplicity, the method of least-squares is recommended for use at the hospitals to estimate values of f (constant of proportionality), c, and M{sub s} required to determine the strength of HDR {sup 192}Ir brachytherapy sources.

07 ISOTOPE AND RADIATION SOURCES↗

Structure of Neutron-rich N = 126 Closed Shell Nuclei

A series of experiments devoted to the study of the neutron-rich N{approx}426 region have been performed at GSI, Darmstadt, within the Rare Isotopes Investigations at GSI (RISING) project. The highlights of the experimental results from these highly successful experiments include the first observation of excited states in three neutron-rich N = 126 closed shell nuclei: (i) In {sup 205}Au{sub 79} the conversion electron decay of the {pi}h{sub 11/2}{sup -1} seconds lived isomeric state into the {pi}d{sub 3/2}{sup -1} ground-state has been observed. In addition the yrast structure has been established up to spin-parity (19/2{sup +}) via the observation of the decay of an isomeric state with configuration {pi}(h{sub 11/2}{sup -1})10(s{sub 1/2}{sup -1});(ii) In {sup 204}Pt{sub 78}, the yrast sequence has been observed following the internal decay of I{sup {pi}} = (5{sup -}), (7{sup -}) and (10{sup +}) isomeric states; (iii) In {sup 203}Ir{sub 77} excited states have been observed following the decay of an isomeric state with structure 'similar' to that in its {sup 205}Au isotone. Shell model calculations have been performed in order to get a deeper understanding of the structure of these N = 126 nuclei. It was found that in order to get a good description for all available information on the N = 126 isotones below lead, both on excitation energies and transition strengths, small modifications of the standard two-body matrix elements were required.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Endovascular Brachytherapy in the Femoropopliteal Segment Using {sup 192}Ir and {sup 188}Re

This report presents a review of the literature on endovascular brachytherapy (EVBT) after percutaneous transluminal angioplasty (PTA) in the femoropopliteal segment. We summarize the pathophysiological changes induced by PTA and EVBT within the vessel wall, technical considerations regarding various radiation sources and their application, the impact of stents on the radial dose profile, recommendations for dosimetry of beta and gamma sources, results of experimental and clinical trials, and the medication required before, during, and after EVBT. We aim to help to identify patients who are eligible for EVBT, to choose an appropriate technical approach, and to initiate adequate antiplatelet and anticoagulant therapy.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma

Purpose: This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation.MethodFifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 ({+-} 90) ml (range, 10-257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan-Meier method. Results: After a median follow-up of 18 (range, 1-27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months. Conclusion: In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Hypofractionated Boost With High-Dose-Rate Brachytherapy and Open Magnetic Resonance Imaging-Guided Implants for Locally Aggressive Prostate Cancer: A Sequential Dose-Escalation Pilot Study

Purpose: To evaluate the feasibility, tolerance, and preliminary outcome of an open MRI-guided prostate partial-volume high-dose-rate brachytherapy (HDR-BT) schedule in a group of selected patients with nonmetastatic, locally aggressive prostatic tumors. Methods and Materials: After conventional fractionated three-dimensional conformal external radiotherapy to 64-64.4 Gy, 77 patients with nonmetastatic, locally aggressive (e.g., perineural invasion and/or Gleason score 8-10) prostate cancer were treated from June 2000 to August 2004, with HDR-BT using temporary open MRI-guided {sup 192}Ir implants, to escalate the dose in the boost region. Nineteen, 21, and 37 patients were sequentially treated with 2 fractions of 6 Gy, 7 Gy, and 8 Gy each, respectively. Neoadjuvant androgen deprivation was given to 62 patients for 6-24 months. Acute and late toxicity were scored according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scoring system. Results: All 77 patients completed treatment as planned. Only 2 patients presented with Grade >=3 acute urinary toxicity. The 3-year probability of Grade >=2 late urinary and low gastrointestinal toxicity-free survival was 91.4% +- 3.4% and 94.4% +- 2.7%, respectively. Rates of 3-year biochemical disease-free survival (bDFS) and disease-specific survival were 87.1% +- 4.1% and 100%, respectively. Conclusions: Boosting a partial volume of the prostate with hypofractionated HDR-BT for aggressive prostate cancer was feasible and showed limited long-term toxicity, which compared favorably with other dose-escalation methods in the literature. Preliminary bDFS was encouraging if one considers the negatively selected population of high-risk patients in this study.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Head-and-Neck Cancer

Purpose: To report the use of high-dose-rate intraoperative radiation therapy (HDR-IORT) for recurrent head-and-neck cancer (HNC) at a single institution. Methods and Materials: Between July 1998 and February 2007, 34 patients with recurrent HNC received 38 HDR-IORT treatments using a Harrison-Anderson-Mick applicator with Iridium-192. A single fraction (median, 15 Gy; range, 10-20 Gy) was delivered intraoperatively after surgical resection to the region considered at risk for close or positive margins. In all patients, the target region was previously treated with external beam radiation therapy (median dose, 63 Gy; range, 24-74 Gy). The 1- and 2-year estimates for in-field local progression-free survival (LPFS), locoregional progression-free survival (LRPFS), distant metastases-free survival (DMFS), and overall survival (OS) were calculated. Results: With a median follow-up for surviving patients of 23 months (range, 6-54 months), 8 patients (24%) are alive and without evidence of disease. The 1- and 2-year LPFS rates are 66% and 56%, respectively, with 13 (34%) in-field recurrences. The 1- and 2-year DMFS rates are 81% and 62%, respectively, with 10 patients (29%) developing distant failure. The 1- and 2-year OS rates are 73% and 55%, respectively, with a median time to OS of 24 months. Severe complications included cellulitis (5 patients), fistula or wound complications (3 patients), osteoradionecrosis (1 patient), and radiation-induced trigeminal neuralgia (1 patient). Conclusions: HDR-IORT has shown encouraging local control outcomes in patients with recurrent HNC with acceptable rates of treatment-related morbidity. Longer follow-up with a larger cohort of patients is needed to fully assess the benefit of this procedure.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Rectal Dose and Source Strength of the High-Dose-Rate Iridium-192 Both Affect Late Rectal Bleeding After Intracavitary Radiation Therapy for Uterine Cervical Carcinoma

Purpose: The purpose of this study was to reconfirm our previous findings that the rectal dose and source strength both affect late rectal bleeding after high-dose-rate intracavitary brachytherapy (HDR-ICBT), by using a rectal dose calculated in accordance with the definitions of the International Commission on Radiation Units and Measurements Report 38 (ICRU{sub RP}) or of dose-volume histogram (DVH) parameters by the Groupe Europeen de Curietherapie of the European Society for Therapeutic Radiology and Oncology. Methods and Materials: Sixty-two patients who underwent HDR-ICBT and were followed up for 1 year or more were studied. The rectal dose for ICBT was calculated by using the ICRP{sub RP} based on orthogonal radiographs or the DVH parameters based on computed tomography (CT). The total dose was calculated as the biologically equivalent dose expressed in 2-Gy fractions (EQD{sub 2}). The relationship between averaged source strength or the EQD{sub 2} and late rectal bleeding was then analyzed. Results: When patients were divided into four groups according to rectal EQD{sub 2} ({>=} or <median dose) and source strength ({>=} or <2.4 cGy.m{sup 2}.h{sup -1}), the group with both a high EQD{sub 2} and a high source strength showed a significantly greater probability of rectal bleeding for ICRU{sub RP}, D{sub 2cc}, and D{sub 1cc}. The patients with a median rectal dose above the threshold level did not show a greater frequency of rectal bleeding unless the source strength exceeded 2.4 cGy.m{sup 2}.h{sup -1}. Conclusions: Our results obtained with data based on ICRU{sub RP} and CT-based DVH parameters indicate that rectal dose and source strength both affect rectal bleeding after HDR-ICBT.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Long-Term Clinical and Cosmetic Outcomes After Breast Conservation Treatment for Women With Early-Stage Breast Carcinoma According to the Type of Breast Boost

Purpose: The present study was performed to compare outcomes after breast conservation treatment with iridium-192 implant boost vs. electron boost. Methods and Materials: From 1977 to 1983, 141 patients were treated with whole breast radiotherapy followed by iridium-192 boost after breast-conserving surgery. They were matched 1:1 to patients treated with electron boost. Outcome measures included survival, local recurrence, cosmesis, and complications. Results: Median follow-up was 16.7 and 12.6 years for the implant vs. electron groups (p < 0.001). Rates of local recurrence, freedom from distant metastases, and overall survival at 10/20 years did not differ between the groups, nor did patterns of first failure. Patients in the electron group were more likely to have excellent/good cosmesis than those in the implant group 1 year after radiotherapy (p = 0.014); this trend continued through 10 years but did not reach statistical significance at years 5/10. Complication rates were similar, although patients receiving electron boost seemed less likely to develop breast fibrosis than did those receiving implant boost (23/141 vs. 58/141, respectively, incidence rate ratio 0.7, p = 0.17). Conclusions: Twenty-year data demonstrate no difference in rates of local recurrence, freedom from distant metastases, overall survival, or patterns of failure between groups treated with these two well-described radiotherapy boost techniques. Better cosmesis was observed in the electron group 1 year after radiotherapy, with a trend continuing for 10 years. The incidence of complications was similar between the groups, with a trend toward increased fibrosis in patients receiving implant boost.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Dose Modeling of Noninvasive Image-Guided Breast Brachytherapy in Comparison to Electron Beam Boost and Three-Dimensional Conformal Accelerated Partial Breast Irradiation

Purpose: To perform dose modeling of a noninvasive image-guided breast brachytherapy (NIIGBB) for comparison to electrons and 3DCRT. Methods and Materials: The novel technology used in this study is a mammography-based, noninvasive breast brachytherapy system whereby the treatment applicators are centered on the planning target volume (PTV) to direct {sup 192}Ir emissions along orthogonal axes. To date, three-dimensional dose modeling of NIIGBB has not been possible because of the limitations of conventional treatment planning systems (TPS) to model variable tissue deformation associated with breast compression. In this study, the TPS was adapted such that the NIIGBB dose distributions were modeled as a virtual point source. This dose calculation technique was applied to CT data from 8 patients imaged with the breast compressed between parallel plates in the cranial-caudal and medial-lateral axes. A dose-volume comparison was performed to simulated electron boost and 3DCRT APBI. Results: The NIIGBB PTV was significantly reduced as compared with both electrons and 3DCRT. Electron boost plans had a lower D{sub min} than the NIIGBB technique but higher V{sub 100}, D{sub 90}, and D{sub 50}. With regard to PTV coverage for APBI, the only significant differences were minimally higher D{sub 90}, D{sub 100}, V{sub 80}, and V{sub 90}, with 3DCRT and D{sub max} with NIIGBB. The NIIGBB technique, as compared with electrons and 3D-CRT, achieved a lower maximum dose to skin (60% and 10%, respectively) and chest wall/lung (70-90%). Conclusions: NIIGBB achieves a PTV that is smaller than electron beam and 3DCRT techniques. This results in significant normal tissue sparing while maintaining dosimetric benchmarks to the target tissue.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Retrospective Analysis of Local Control and Cosmetic Outcome of 147 Periorificial Carcinomas of the Face Treated With Low-Dose Rate Interstitial Brachytherapy

Purpose: Skin cancer is the most common malignancy in white populations. We evaluated the local cure rate and cosmetic outcome of patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the face treated with low-dose rate brachytherapy. Methods and Materials: Between February 1990 and May 2000, 147 facial carcinomas in 132 patients were treated by {sup 192}Ir wire implantation. Side effects of brachytherapy were noted. Follow-up was 2 years or more. Locoregional recurrence-free survival (LRFS) and overall survival were recorded. Group A included patients treated by primary brachytherapy, and Group B included those treated after recurrence. Results: A total of 121 carcinomas were BCCs (82.3%) and 26 were SCCs (17.7%); the median tumor size was 10 mm. Of the tumors, 86 (58.5%) were in men and 61 (41.5%) were in women; the median age was 71 years. Group A comprised 116 lesions (78.9%), and Group B, 31 (21.1%). There were 17 relapses (11.6%) after a median follow-up of 72 months: 12 local, 4 nodal, and 1 local and nodal. Locoregional-free survival was 96.6% at 2 years and 87.3% at 5 years. Five-year LRFS was 82.6% in men and 93.3% in women (p = 0.027). After adjustment for gender, LRFS was better after primary treatment than after recurrence (hasard ratio HR, 2.91; 95% confidence interval, 1.06-8.03; p = 0.039). Five-year LRFS was 90.4% for BCC and 70.8% for SCC (p = 0.03). There were no Grade 3 complications. Conclusions: Low-dose rate brachytherapy offers good local control and cosmetic outcome in patients with periorificial skin carcinomas, with no Grade 3 complications. Brchytherapy is more efficient when used as primary treatment.

62 RADIOLOGY AND NUCLEAR MEDICINE↗